Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 939-066-9 | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Genetic toxicity: in vitro
Administrative data
- Endpoint:
- in vitro gene mutation study in mammalian cells
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- August 10, 2012 - November 5, 2012
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 012
- Report date:
- 2012
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 476 (In Vitro Mammalian Cell Gene Mutation Test)
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Type of assay:
- in vitro mammalian cell gene mutation tests using the thymidine kinase gene
Test material
- Reference substance name:
- diammonium hexadecanoate octadecanoate
- EC Number:
- 939-066-9
- Molecular formula:
- Not applicable (a generic molecular formula cannot be provided for this specific UVCB substance).
- IUPAC Name:
- diammonium hexadecanoate octadecanoate
- Test material form:
- liquid
Constituent 1
Method
- Target gene:
- Thymidine kinase, TK +/-
Species / strain
- Species / strain / cell type:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- with and without
- Metabolic activation system:
- S9-mix
- Test concentrations with justification for top dose:
- Experiment I:
With metabolic activation: 1.0, 2.0, 5.0, 10.0, 25.0, 50.0, 100.0 and 200.0 µg/mL (4h exposure period)
Without metabolic activation: 1.0, 2.0, 5.0, 10.0, 20.0, 40.0, 50.0 and 80.0 µg/mL. (4h exposure period)
Experiment II:
With metabolic activation: 3.0, 7.0, 15.0, 30.0, 60.0, 90.0, 150.0 and 180.0 µg/mL (4h exposure period)
Without metabolic activation: 0.2, 0.5, 1.0, 3.0, 8.0, 10.0, 15.0 and 20.0 µg/mL (24h exposure period) - Vehicle / solvent:
- - Vehicle(s)/solvent(s) used: RPMI cell culture medium (RPMI + 5% HS)
- Justification for choice of solvent/vehicle: Based on the results of the solubility test.
Controlsopen allclose all
- Negative solvent / vehicle controls:
- yes
- Remarks:
- RPMI cell culture medium (RPMI + 5% HS)
- Positive controls:
- yes
- Remarks:
- Without metabolic activation
- Positive control substance:
- ethylmethanesulphonate
- Remarks:
- 300 µg/mL in medium
- Positive controls:
- yes
- Remarks:
- Without metabolic activation
- Positive control substance:
- methylmethanesulfonate
- Remarks:
- 8 and 10 µg/mL in 0.9% NaCl
- Positive controls:
- yes
- Remarks:
- With metabolic activation
- Positive control substance:
- benzo(a)pyrene
- Remarks:
- 1.5 and 2.5 µg/Ml in DMSO
- Details on test system and experimental conditions:
- METHOD OF APPLICATION:
Experiment I: Short-term exposure (4h): 1x10E+07 cells were suspended in 11 mL RPMI medium with 5% horse serum (25 cm2 flasks) and exposed to designated concentrations of the test item either in the presence of absence of metabolic activation. After exposure, test item was removed by centrifugation (200 x g, 10 min) and the cells were washed twice with PBS. Subsequently the cells were suspended in 30 mL complete culture medium and incubated for an expression and growth period. The cell density was determined each day and adjusted to 3x10E+05 cells/mL in a total culture volume of 20 mL, if necessary.
Experiment II: Long-term exposure (24h): 5x10E+06 cells were suspended in 25 mL RPMI medium with 7.5% horse serum (75 cm2 flasks) and exposed to designated concentrations of the test item in the absence of metabolic activation. After exposure, test item was removed by centrifugation (200 x g, 10 min) and the cells were washed twice with PBS. Subsequently 3x10E+05 cells were suspended in 14 mL complete culture medium and incubated for an expression and growth period. The cell density was determined each day and adjusted to 3x10E+05 cells/mL in a total culture volume of 20 mL, if necessary.
DURATION
- Exposure duration:
Experiment 1: 4 hours (with and without metabolic activation)
Experiment II: 4 hours (with metabolic activation) and 24 hours (without metabolic activation)
- Expression time (cells in growth medium): 2 days, at 37 ºC in 5% Co2/95% humidified air.
- Selection time (if incubation with a selection agent): ~ 14 days at 37 ºC in 5% CO2/95% humidified air
SELECTION AGENT (mutation assays): Cells from each experimental group were seeded in four 96-well plates at a density of approximately 2000 cells/well in 200 µL selective medium with TFT.
NUMBER OF REPLICATIONS: 1 replicate per dose (negative control, 2 replicates).
NUMBER OF CELLS EVALUATED: 2000 cells/well. The mutant frequency was calculated by dividing the number of TFT resistant colonies by the number of cells plated for selection, corrected for the plating efficiency of cells from the same culture grown in the absence of TFT.
DETERMINATION OF CYTOTOXICITY:
The toxicity of the test item was determined in pre-experiments up to a maximum concentration of 5 mg/mL. For experiment I (4h exposure) six concentrations (50, 150, 500, 1000, 2000 and 5000 µg/ml) were tested with and without metabolic activation. For the 24h long-term exposure assay (Experiment II, without metabolic activation) six concentrations (0.1, 1.0, 5.0, 10.0, 40.0 and 100.0 µg/mL) were tested. The number of cells at 4h, 24h and 48h after treatment were measured and the relative suspension growths were calculated.
In the main test the following parameters were calculated:
- Mutant frequency (MF)
- Cloning efficiency (CE) and relative cloning efficiency (RCe)
- Suspension growth (SG) and relative suspension growth (RSG)
OTHER EXAMINATIONS:
Colony sizing was performed for the highest concentrations of the test item and for the negative and positive controls. Small colonies were defined by slow growth and/or morphological alteration of the cell close. - Evaluation criteria:
- The test item is considered mutagenic if the following criteria are met:
- The induced mutant frequency meets or exceeds the Global Evaluation Factor (GEF) of 126 mutants per 1E+06 cells.
- A dose-dependent increase in mutant frequency is detected.
Besides, combined with a positive effect in the mutant frequency, an increased occurrence of small colonies (>= 40$ of total colonies) is an indication for potential clastogenic effect and/or chromosomal aberrations. - Statistics:
- The non-parametric Mann-Whitney test was applied to the mutation data to prove the dose groups for any significant difference in mutant frequency compared to the negative/solvent controls.
Results and discussion
Test results
- Key result
- Species / strain:
- mouse lymphoma L5178Y cells
- Metabolic activation:
- with and without
- Genotoxicity:
- negative
- Cytotoxicity / choice of top concentrations:
- no cytotoxicity
- Vehicle controls validity:
- valid
- Positive controls validity:
- valid
- Additional information on results:
- TEST-SPECIFIC CONFOUNDING FACTORS
- Effects of pH: The pH-value of the test item suspension was adjusted with HCl to the physiological range.
- Precipitation: Precipitation of the test item was noted in the pre-experiment for experiment I with metabolic activation at concentrations of 500 µg/mL and higher and without metabolic activation at concentrations of 150 µg/mL and higher. No precipitations were noted in experiment I and II with and without metabolic activation and in pre-experiment II without metabolic activation.
RANGE-FINDING/SCREENING STUDIES: The selection of the concentrations used in the main experiments was based on data from the pre-experiments. In experiment I 200.0 µg/mL (with metabolic activation) and 80 µg/mL (without metabolic activation) were selected as the highest concentrations. In experimental II 180.0 µg/mL (with metabolic activation) and 20.0 µg/mL (without metabolic activation) were selected as the highest concentrations.
TOXICITY: Growth inhibition was observed in experiment I and II with and without metabolic activation.
MUTAGENICITY: In experiment I and II no biologically relevant increase of mutants was found after treatment with the test item (with and without metabolic activation). The Global Evaluation Factor (GEF) was exceed by the induced mutant frequency at only one concentration (100 µg/mL) in experiment I with metabolic activation. The exceeded threshold of the GEF could not be verified in the second independent experiment with metabolic activation. Therefore, this effect was considered as not biologically relevant.
CLASTOGENICITY: In experiment I and II colony sizing showed no clastogenic effects induced by the test item under the experimental conditions (with and without metabolic activation).
CONTROLS: EMS, MMS and B[a]P were used as positive controls and showed distinct and biologically relevant effects in mutation frequency. MMS and B[a]P significantly increased the number of small colonies, thus proving the efficiency of the test system to indicate potential clastogenic effects.
Any other information on results incl. tables
Summary: Experiment I and II with metabolic activation:
|
Test groups |
Conc [µg/ml] |
RCE [µg/ml] |
RTG [%] |
MF [mutants/106cells] |
IMF [mutants/106cells] |
GEF exceded |
Statistical Significance |
Precipitate |
Exp I |
C1 |
0 |
100.0 |
100.0 |
129.1 |
/ |
/ |
- |
- |
C2 |
/ |
/ |
- |
- |
|||||
1 |
1.0 |
94.8 |
97.9 |
114.7 |
-14.4 |
- |
- |
- |
|
2 |
2.0 |
79.9 |
86.2 |
116.1 |
-13.0 |
- |
- |
- |
|
3 |
5.0 |
90.4 |
78.8 |
148.6 |
19.5 |
- |
- |
- |
|
4 |
10.0 |
87.6 |
72.7 |
122.3 |
-6.8 |
- |
- |
- |
|
5 |
25.0 |
81.1 |
70.6 |
147.0 |
17.9 |
- |
- |
- |
|
6 |
50.0 |
78.7 |
51.2 |
155.2 |
26.1 |
- |
- |
- |
|
7 |
100.0 |
74.2 |
21.8 |
289.1 |
160.0 |
+ |
+ |
- |
|
10 |
200.0 |
72.1 |
12.7 |
225.7 |
96.9 |
- |
+ |
- |
|
B[a]P |
2.5 |
60.7 |
25.4 |
848.6 |
719.5 |
+ |
+ |
- |
|
Exp II |
C1 |
0 |
100.0 |
100.0 |
86.6 |
/ |
/ |
/ |
- |
C2 |
/ |
/ |
/ |
- |
|||||
3 |
3.0 |
99.7 |
91.5 |
86.6 |
4.9 |
- |
- |
- |
|
4 |
7.0 |
109.7 |
98.1 |
91.4 |
-14.0 |
- |
- |
- |
|
5 |
15.0 |
82.1 |
74.6 |
72.5 |
16.1 |
- |
- |
- |
|
6 |
30.0 |
88.3 |
81.9 |
102.7 |
1.4 |
- |
- |
- |
|
7 |
60.0 |
89.6 |
48.7 |
101.4 |
14.9 |
- |
- |
- |
|
8 |
90.0 |
84.5 |
33.0 |
119.1 |
32.5 |
- |
+ |
- |
|
10 |
150.0 |
77.5 |
24.3 |
110.6 |
24.0 |
- |
+ |
- |
|
11 |
180.0 |
64.4 |
11.9 |
151.2 |
64.7 |
- |
+ |
- |
|
B[a]P |
1.5 |
67.2 |
37.8 |
690.7 |
604.1 |
+ |
+ |
- |
Summary: Experiment I and II without metabolic activation:
|
Test groups |
Conc [µg/ml] |
RCE [µg/ml] |
RTG [%] |
MF [mutants/106cells] |
IMF [mutants/106cells] |
GEF exceded |
Statistical Significance |
Precipitate |
Exp I |
C1 |
0 |
100.0 |
100.0 |
121.4 |
/ |
/ |
- |
- |
C2 |
/ |
/ |
- |
- |
|||||
3 |
1.0 |
116.3 |
114.4 |
111.2 |
-10.3 |
- |
- |
- |
|
4 |
2.0 |
100.7 |
98.6 |
123.1 |
1.7 |
- |
- |
- |
|
5 |
5.0 |
88.4 |
81.6 |
180.2 |
58.8 |
- |
- |
- |
|
6 |
10.0 |
104.2 |
98.0 |
128.9 |
7.4 |
- |
- |
- |
|
7 |
20.0 |
84.4 |
42.4 |
216.3 |
94.8 |
- |
+ |
- |
|
8 |
40.0 |
100.7 |
9.3 |
145.2 |
23.8 |
- |
- |
- |
|
9 |
50.0 |
78.3 |
15.1 |
180.2 |
58.8 |
- |
+ |
- |
|
12 |
80.0 |
57.1 |
10.1 |
232.9 |
111.5 |
- |
+ |
- |
|
EMS |
300 |
77.1 |
64.9 |
687.4 |
566.0 |
+ |
+ |
- |
|
MMS |
10 |
64.8 |
45.2 |
690.6 |
569.2 |
+ |
+ |
- |
|
Exp II |
C1 |
0 |
100.0 |
100.0 |
60.7 |
/ |
/ |
/ |
- |
C2 |
/ |
/ |
/ |
- |
|||||
2 |
0.2 |
105.0 |
95.4 |
67.2 |
6.6 |
- |
- |
- |
|
3 |
0.5 |
110.1 |
100.8 |
60.0 |
-0.7 |
- |
- |
- |
|
4 |
1.0 |
94.4 |
91.2 |
68.3 |
7.6 |
- |
- |
- |
|
5 |
3.0 |
85.1 |
76.6 |
83.2 |
22.5 |
- |
- |
- |
|
7 |
8.0 |
108.4 |
70.6 |
89.1 |
28.4 |
- |
- |
- |
|
8 |
10.1 |
95.8 |
52.2 |
67.2 |
6.5 |
- |
- |
- |
|
9 |
15.0 |
91.6 |
22.4 |
82.4 |
21.7 |
- |
+ |
- |
|
10 |
20.0 |
80.4 |
7.7 |
83.9 |
23.2 |
- |
- |
- |
|
EMS |
200 |
61.4 |
24.2 |
1617.7 |
1557.0 |
+ |
+ |
- |
|
MMS |
8 |
65.0 |
17.0 |
725.8 |
665.1 |
+ |
+ |
- |
C: Negative controls
RCE: Relative Cloning Efficiency
RTG: Relative Total Growth
MF: Mutant Frequency
IMF: Induced Mutant Frequency
GEF: Global Evaluation Factor
Statistical Significance: Mann Whitney test, p<0.05
B[a]P: Benzo[a]pyrene
EMS: Ethylmethanesulfonate
MMS: Methylmethanesulfonate
Applicant's summary and conclusion
- Conclusions:
- Test item Fatty acids, C16-18 (even numbered), ammonium salts was considered to be non-mutagenic in the in vitro mammalian cell gene mutation assay (thymidine kinase locus) in mouse lymphoma L5178Y cells, under test conditions (with and without metabolic activation.
- Executive summary:
An in vitro gene mutation assay (thymidine kinase locus) in mouse lymphoma L5178Y cells was performed on test item Fatty acids, C16 -18 (even numbered), ammonium salts in accordance with OECD Guideline 476. The selection of the concentrations used in the main experiment was based on the data from the pre-experiments. In experiment I 200.0 µg/mL (with metabolic activation, 4h short-term exposure) and 80.0 µg/mL (without metabolic activation, 4h short-term exposure) were selected as the highest concentrations. In experiment II 180.0 µg/mL (with metabolic activation, 4h short-term exposure) and 20.0 µg/mL (without metabolic activation, 24h long-term exposure) were selected as the highest concentrations. No precipitation was noted in the main experiment. Growth inhibition was observed in experiment I and II with and without metabolic activation. In experiment I and II no biologically relevant increase of mutants was found after treatment with the test item (with and without metabolic activation). The Global Evaluation Factor (GEF) was exceed by the induced mutant frequency at only one concentration (100 µg/mL) in experiment I with metabolic activation. The exceeded threshold of the GEF could not be verified in the second independent experiment with metabolic activation. Therefore, this effect was considered as not biologically relevant. Additionally, in experiment I and II colony sizing showed no clastogenic effects induced by the test item under the experimental conditions (with and without metabolic activation). EMS, MMS and B[a]P were used as positive controls and showed distinct and biologically relevant effects in mutation frequency. MMS and B[a]P significantly increased the number of small colonies, thus proving the efficiency of the test system to indicate potential clastogenic effects. Based on these results, test item Fatty acids, C16-18 (even numbered), ammonium salts was considered to be non-mutagenic in the in vitro mammalian cell gene mutation assay (thymidine kinase locus) in mouse lymphoma L5178Y cells, under test conditions (with and without metabolic activation.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.